The Science of Listening
June 15, 2026
Why patient voices must shape rare disease innovation
4 min read
False
The voices driving change and progress in medicine making. Explore stories, interviews, and community highlights that inspire and inform.
We interview Scott Billman, one of the judges of the ISPE Facility of the Year Awards, to learn more about the 2025 winners and the trends impacting facilities.
All the latest Medicine Maker articles.
June 9, 2026
Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody
4 min read
June 8, 2026
Antoinette Gawin discusses leadership, innovation in blood and cell therapy, and the global systems shaping access to advanced medicine
10 min read
June 8, 2026
Legend and Kelonia reveal 100 percent response rates in phase 1 trials, dual CAR T opens doors for kidney transplant patients, and iPDSC therapy beefs up failing hearts
5 min read
June 5, 2026
The $787M financing points to a new global architecture in biotech
5 min read
June 4, 2026
IBTV speaks with industry leaders at Advanced Therapies London 2026 to explore how a tougher funding environment is sharpening focus on scalability, cost-efficiency, partnerships, and commercialization in advanced therapies
1 min read
June 3, 2026
Jonathan Maurer of the University of Geneva discusses his work with Sanofi and Waters – and why good analytical science has a lot in common with good cooking
3 min read
June 2, 2026
Why drug trials exclude pregnant women – and how simulation could change that
7 min read
June 2, 2026
Datroway and Hepcludex secure notable FDA approvals, while Outlook wins its bevacizumab appeal, BioMarin reports phase 3 VOXZOGO data, and BMS partners with Anthropic
6 min read
June 1, 2026
Kelly Broster of Thermo Fisher Scientific explains why GLP-1 peptides are exposing the limits of traditional analytical workflows
12 min read
June 1, 2026
Verve reports phase 1 data for one-time PCSK9 base editing; plus: neuroprotective gene therapy, non-viral DNA delivery, tumour-activated CAR-T, and in vivo CAR-M
3 min read
False